SCYNEXIS Expands FURI Protocol to a Broader Range of Refractory Serious Fungal Infections, Building on Ibrexafungerp's Positive Data and Favorable Toxicology Profile Observed to Date

Stock Information for SCYNEXIS Inc.

Loading

Please wait while we load your information from QuoteMedia.